| abstract |
The use of EP4 receptor antagonist compounds represented by Formula (I) (or pharmaceutically acceptable salts thereof) as defined herein is provided for treating cancer or inflammatory disease by administering such an EP4 antagonist alone or in combination with an antibody therapy, radiation therapy, anti-metabolite chemotherapy to a subject in need thereof. |